AI Engines For more Details: Perplexity Kagi Labs You
Antiviral Activity: Vidarabine is a nucleoside analog antiviral medication that inhibits the replication of herpes simplex virus by interfering with viral DNA synthesis. It is effective against both herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2).
Treatment of Herpes Simplex Keratitis: Vidarabine is commonly used as a topical ophthalmic ointment or solution for the treatment of herpes simplex keratitis, a viral infection of the cornea that can cause eye pain, redness, tearing, and blurred vision. By inhibiting viral replication, vidarabine helps reduce the severity and duration of symptoms associated with herpes simplex keratitis.
Herpes Simplex Virus Infections: In addition to herpes simplex keratitis, vidarabine may be used in the treatment of other localized herpes simplex virus infections, such as herpes labialis (cold sores) and herpes genitalis (genital herpes). It is applied directly to the affected area as a topical medication to suppress viral replication and promote healing.
Mechanism of Action: Vidarabine exerts its antiviral effects by being phosphorylated intracellularly to its active form, vidarabine triphosphate. Vidarabine triphosphate competes with deoxyadenosine triphosphate (dATP) for incorporation into viral DNA by the viral DNA polymerase. Once incorporated, vidarabine triphosphate terminates viral DNA chain elongation, leading to inhibition of viral replication.
Topical Administration: Vidarabine is typically administered as a topical ophthalmic ointment or solution for the treatment of herpes simplex keratitis. It is applied directly to the affected eye(s) several times daily as directed by a healthcare provider. The frequency and duration of treatment may vary depending on the severity of the infection and the patient's response to therapy.
Adverse Effects: Common side effects associated with vidarabine therapy may include local irritation or burning sensation at the application site, transient blurred vision, and increased lacrimation (tearing). These side effects are usually mild and resolve spontaneously with continued use.
Patient Monitoring: Patients receiving vidarabine therapy should be monitored regularly by a healthcare provider to assess treatment response, monitor for adverse effects, and ensure proper management of the underlying herpes simplex virus infection. Any worsening of symptoms or development of new ocular symptoms should be reported promptly to a healthcare provider.
Contraindications: Vidarabine is contraindicated in patients with known hypersensitivity to the medication or any of its components. It should not be used in patients with active fungal, bacterial, or viral infections of the eye other than herpes simplex keratitis.
Pregnancy and Lactation: The safety of vidarabine use during pregnancy or breastfeeding has not been well established. Healthcare providers should weigh the potential benefits and risks of treatment when considering the use of vidarabine in pregnant or lactating women.
Drug Interactions: There are no significant drug interactions reported with vidarabine. However, patients should inform their healthcare provider about all medications, including prescription, over-the-counter, and herbal products, before starting vidarabine therapy to prevent potential drug interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.7 | 3.7 | |
| Age-Related Macular Degeneration and Glaucoma | 0.7 | 0.2 | 2.5 |
| Allergic Rhinitis (Hay Fever) | 1.7 | 1.5 | 0.13 |
| Allergies | 4.8 | 1.3 | 2.69 |
| Allergy to milk products | 1.2 | 0.8 | 0.5 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 3.3 | 5.2 | -0.58 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.7 | 1.29 |
| Ankylosing spondylitis | 3.7 | 1.1 | 2.36 |
| Anorexia Nervosa | 0.2 | 1.6 | -7 |
| Antiphospholipid syndrome (APS) | 1.2 | 0.5 | 1.4 |
| Asthma | 0.7 | 0.5 | 0.4 |
| Atherosclerosis | 1.1 | 1.3 | -0.18 |
| Atrial fibrillation | 2.6 | 1.5 | 0.73 |
| Autism | 6.6 | 6 | 0.1 |
| Barrett esophagus cancer | 0.8 | 0.3 | 1.67 |
| benign prostatic hyperplasia | 0.3 | 0.3 | |
| Bipolar Disorder | 1.2 | 0.7 | 0.71 |
| Brain Trauma | 0.8 | 0.4 | 1 |
| Carcinoma | 3.4 | 2.3 | 0.48 |
| Celiac Disease | 2 | 3.1 | -0.55 |
| Cerebral Palsy | 1.5 | 0.9 | 0.67 |
| Chronic Fatigue Syndrome | 3.4 | 4.8 | -0.41 |
| Chronic Kidney Disease | 1.5 | 1.3 | 0.15 |
| Chronic Lyme | 0.4 | -0.4 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.3 | 0.3 | 6.67 |
| Chronic Urticaria (Hives) | 2.1 | 0.2 | 9.5 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.1 | 0.36 |
| Colorectal Cancer | 3.7 | 1 | 2.7 |
| Constipation | 0.7 | 0.8 | -0.14 |
| Coronary artery disease | 1.3 | 0.9 | 0.44 |
| COVID-19 | 9.3 | 8.9 | 0.04 |
| Crohn's Disease | 6.9 | 3.7 | 0.86 |
| cystic fibrosis | 1 | 0.7 | 0.43 |
| deep vein thrombosis | 1 | 0.6 | 0.67 |
| Depression | 7 | 6 | 0.17 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.3 | 1.6 | -0.23 |
| Endometriosis | 2.8 | 0.7 | 3 |
| Eosinophilic Esophagitis | 0.3 | 0.4 | -0.33 |
| Epilepsy | 2.6 | 1.7 | 0.53 |
| Fibromyalgia | 2.2 | 1.2 | 0.83 |
| Functional constipation / chronic idiopathic constipation | 3.6 | 2.2 | 0.64 |
| gallstone disease (gsd) | 2.2 | 0.9 | 1.44 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 1.3 | -0.18 |
| Generalized anxiety disorder | 2.4 | 1.2 | 1 |
| giant cell arteritis | 0.4 | -0.4 | |
| Glioblastoma | 0.3 | -0.3 | |
| Graves' disease | 1.1 | 1.6 | -0.45 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 1.9 | 1 | 0.9 |
| Hidradenitis Suppurativa | 1.1 | 0.4 | 1.75 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.7 | 0.9 | 2 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0 | 0 |
| hyperglycemia | 0.3 | 1.2 | -3 |
| Hyperlipidemia (High Blood Fats) | 0.8 | 0.5 | 0.6 |
| hypersomnia | 1 | -1 | |
| hypertension (High Blood Pressure | 1.8 | 4.2 | -1.33 |
| Hypothyroidism | 0.8 | -0.8 | |
| Hypoxia | 0.4 | 0.4 | |
| IgA nephropathy (IgAN) | 2.4 | -2.4 | |
| Inflammatory Bowel Disease | 3.4 | 4.4 | -0.29 |
| Insomnia | 1 | 0.5 | 1 |
| Intelligence | 0.7 | 0.7 | |
| Intracranial aneurysms | 0.9 | 0.5 | 0.8 |
| Irritable Bowel Syndrome | 3.3 | 2.6 | 0.27 |
| Liver Cirrhosis | 4.4 | 2.8 | 0.57 |
| Long COVID | 5.1 | 6.9 | -0.35 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 1 | 0.9 | 0.11 |
| ME/CFS with IBS | 0.8 | 2.2 | -1.75 |
| ME/CFS without IBS | 1.4 | 1.9 | -0.36 |
| Menopause | 1.9 | 1.9 | |
| Metabolic Syndrome | 7.4 | 6.4 | 0.16 |
| Mood Disorders | 9.7 | 6 | 0.62 |
| multiple chemical sensitivity [MCS] | 1.1 | 0.5 | 1.2 |
| Multiple Sclerosis | 4.1 | 3.2 | 0.28 |
| Multiple system atrophy (MSA) | 1.8 | 0.8 | 1.25 |
| Neuropathy (all types) | 0.8 | 0.3 | 1.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.4 | 4 | -0.67 |
| NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
| Obesity | 8.4 | 3 | 1.8 |
| obsessive-compulsive disorder | 5.4 | 2.7 | 1 |
| Osteoarthritis | 1.8 | 1.8 | |
| Osteoporosis | 1.3 | 0.7 | 0.86 |
| pancreatic cancer | 0.5 | 0.5 | |
| Parkinson's Disease | 2.5 | 2.8 | -0.12 |
| Polycystic ovary syndrome | 1.8 | 1.2 | 0.5 |
| Postural orthostatic tachycardia syndrome | 0.4 | 0.3 | 0.33 |
| Premenstrual dysphoric disorder | 1.3 | 0.2 | 5.5 |
| primary biliary cholangitis | 0.4 | 0.8 | -1 |
| Psoriasis | 4.5 | 1 | 3.5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.7 | 3.2 | 0.78 |
| Rosacea | 0.5 | 0.7 | -0.4 |
| Schizophrenia | 5.5 | 1.5 | 2.67 |
| scoliosis | 0.6 | -0.6 | |
| Sjögren syndrome | 2.9 | 3 | -0.03 |
| Sleep Apnea | 1.1 | 0.9 | 0.22 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.3 | 0.3 | 3.33 |
| Stress / posttraumatic stress disorder | 2.7 | 1.2 | 1.25 |
| Systemic Lupus Erythematosus | 3.7 | 1.3 | 1.85 |
| Tic Disorder | 0.4 | 1.2 | -2 |
| Tourette syndrome | 0 | 0.2 | 0 |
| Type 1 Diabetes | 3 | 2.1 | 0.43 |
| Type 2 Diabetes | 7.2 | 4.3 | 0.67 |
| Ulcerative colitis | 3.1 | 3.3 | -0.06 |
| Unhealthy Ageing | 4.5 | 1.3 | 2.46 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.